Preventive MedicineSEVEN-YEAR STUDY OF HEPATITIS B VACCINE EFFICACY IN INFANTS FROM AN ENDEMIC AREA (SENEGAL)
References (31)
- et al.
Lack of perinatal transmission of hepatitis B virus infection in Senegal, West Africa
J Paediatrics
(1985) - et al.
Hepatitis B virus infection m two Gambian villages
Lancet
(1983) - et al.
Hepatocellular carcinoma and hepatitis B virus. A prospective study in 22 707 men in Taiwan
Lancet
(1981) - et al.
Serological markers of hepatitis B virus and alpha-fetoprotein levels preceding primary hepatocellular carcinoma in Alaskan Eskimos
Lancet
(1982) - et al.
Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain
Lancet
(1981) - et al.
Immunisation against hepatitis B m man
Lancet
(1976) - et al.
Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, medical staff
Lancet
(1981) - et al.
Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units II, haemodialysis patients
Lancet
(1981) - et al.
Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine
Lancet
(1983) - et al.
Hepatitis B vaccination: how long does protection last?
Lancet
(1984)
Efficacy of hepatitis B vaccine in prevention of an early HBsAg carrier state in children Controlled trial in an endemic area (Senegal)
Lancet
Long term efficacy of hepatitis B vaccine in infants from an endemic area
Ann Virol (Inst Pasteur)
Antibodies to a synthetic peptide from the pre-S 120-145 region of the hepatitis B virus envelope are virus-neutralizing
Vaccine
Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal
Prog Med Virol
An age related point prevalence study of markers of hepatitis B virus infection in Kenya
East Afr Med J
Cited by (126)
Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine
2015, VaccineCitation Excerpt :The HBsAg based vaccine against HBV has been available since the early 1980s and shown highly protective and safe efficacy. However, 5–15% of normal vaccine recipients considered as non-responders to hepatitis B vaccination as well as patients with a chronic liver disease failed to develop detectable specific antibodies and remained susceptible to HBV even after the hepatitis B vaccination according to the recommended three-dose schedule [27,28]. Thus, there has been a need for a more immunogenic vaccine and vaccine adjuvant for enhanced protective immunity.
CD8α<sup>-</sup> Dendritic Cells Induce Antigen-Specific T Follicular Helper Cells Generating Efficient Humoral Immune Responses
2015, Cell ReportsCitation Excerpt :In particular, CD8α− DCs were utilized to increase the number of ASCs specific to HBsAg, the immunogen of currently available hepatitis B vaccine (Figure 7F). Although the current hepatitis B vaccine is very effective, ∼5%–15% of vaccines fail to develop humoral immune responses (Coursaget et al., 1986; Hadler et al., 1986). Conjugation of HBsAg with CD8α− DC targeting antibody would be an alternative for hepatitis B vaccine non-responders.
17. CURRENT ISSUES IN HEPATITIS B VACCINES
2004, Principles of Medical BiologyCitation Excerpt :Specifically, a protective level of anti-HBs was defined as 10 IU/l against an international standard (Centers for Disease Control, 1987; Stevens et al., 1984). Various studies have also demonstrated that the risk of HBV infection increases as anti-HBs levels decline to 10 IU/l (Coursaget et al., 1986; Hadler et al., 1986; Stevens et al., 1984; Taylor & Stevens, 1988). For example, Hadler et al. (1986) reported in a follow-up study of vaccinated homosexual men an overall incidence of HBV infection of 2.9 per 100 person years with nearly 75% occurring in subjects with anti-HBs titres < 10 IU/l at the time of infection and only a few with anti-HBs titres > 50 IU/l.
Seroprevalence of anti-HBs antibodies and the need for booster vaccination in children under 5 years of age born to HBsAg-negative mothers
2021, Asian Pacific Journal of Tropical MedicineRevaccination against hepatitis B in late teenagers who received vaccination during infancy: Yes or no?
2018, Human Vaccines and Immunotherapeutics